{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:53:00Z","timestamp":1787028780692,"version":"build-2736575974"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>There is accumulating evidence that treatment of chronic hepatitis C (HCV) leads to improvements in liver fibrosis. We aimed to investigate the improvement in fibrosis stage following treatment with direct-acting antivirals (DAAs) and factors associated with fibrosis regression. Fibroscan\u00ae was performed for patients treated with DAAs, at least 3 years post-HCV eradication. The fibrosis stage at the onset of treatment was compared with the current fibrosis stage. A total of 209 patients were enrolled in this study (56% males; age 58.8 \u00b1 13.3 years; age at treatment 54 \u00b1 10.9 years). Genotype subgrouping was as follows: 1a (16%), 1b (58%), 2a (4%), 3 (18%), and 4a (2%). Overall, 71% of patients were considered treatment-na\u00efve, with a mean follow-up time of 4.5 \u00b1 1.3 years. Fibrosis improvement was observed among 57% of patients; fibrosis progression was seen among 7% of patients and no change was seen in 36% of patients. Moreover, 28% of these patients regressed from F3\/F4 to F2 or less. In our multivariable analysis, the age at treatment and advanced fibrosis stage were found to be factors significantly associated with fibrosis regression. In conclusion, fibrosis improvement was observed among 57% of HCV patients after treatment with DAAs. Age and advanced fibrosis at baseline were found to be factors associated with fibrosis regression.<\/jats:p>","DOI":"10.3390\/life13091872","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:59:31Z","timestamp":1693907971000},"page":"1872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-3308","authenticated-orcid":false,"given":"Naim","family":"Abu-Freha","sequence":"first","affiliation":[{"name":"Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Abu-Kosh","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Soroka University Medical Center, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yardeni","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaffa","family":"Ashur","sequence":"additional","affiliation":[{"name":"Medical Management Unit, Soroka University Medical Center, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Abu-Arar","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Soroka University Medical Center, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baha","family":"Yousef","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulamit","family":"Monitin","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Weissmann","sequence":"additional","affiliation":[{"name":"Soroka Clinical Research Center, Soroka University Medical Center, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Etzion","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology and Hepatology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"ref_1","unstructured":"(2023, June 01). HCV Updates of the World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/13814788.2022.2056161","article-title":"Chronic hepatitis C: Diagnosis and treatment made easy","volume":"28","author":"Elhoashla","year":"2022","journal-title":"Eur. J. Gen. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hep.29557","article-title":"Portal pressure and liver stiffness measurements in the prediction of Liver fibrosis regression after sustained virological response in recurrent hepatitis C","volume":"67","author":"Mauro","year":"2018","journal-title":"Hepatology"},{"key":"ref_6","unstructured":"World Health Organization (2016). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021, WHO. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf;jsessionid=60A93ADD1A191FF6A0FA823314D24C43?sequence=1."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.20517\/2394-5079.2022.13","article-title":"Changes in hepatic Liver fibrosis and incidence of HCC following direct-acting antiviral treatment of F3 chronic hepatitis c patients: A prospective observational study","volume":"8","author":"Shiha","year":"2022","journal-title":"Hepatoma Res."},{"key":"ref_8","first-page":"4961919","article-title":"Long-Term Impact of Hepatitis C Virus Eradication on Liver Stiffness in Egyptian Patients","volume":"20","author":"Zakareya","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic Liver fibrosis who achieved SVR following DAAs: A prospective study","volume":"27","author":"Shiha","year":"2020","journal-title":"J. Viral. Hepat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced Liver fibrosis or cirrhosis: A meta-analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s11894-014-0372-6","article-title":"Utilization of FibroScan in clinical practice","volume":"16","author":"Bonder","year":"2014","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/gut.2006.111302","article-title":"Reproducibility of transient elastography in the evaluation of liver Liver fibrosis in patients with chronic liver disease","volume":"56","author":"Fraquelli","year":"2007","journal-title":"Gut"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3350\/cmh.2020.0018","article-title":"Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy","volume":"26","author":"Huang","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An Archives study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jgh.14707","article-title":"Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response","volume":"34","author":"Fernandes","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41598-021-03272-1","article-title":"Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents","volume":"7","author":"Yoo","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100347","DOI":"10.1016\/j.aohep.2021.100347","article-title":"Reply to: The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population","volume":"25","author":"Trivedi","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sato, S., Kawai, H., Sato, S., Iwasaki, H., Omori, M., Kita, Y., Ikeda, Y., Awatsu, T., Murata, A., and Taniguchi, G. (2022). Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02575-5"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10620-017-4749-x","article-title":"Direct-Acting Antiviral Therapy for Chronic HCV Infection Results in Liver Stiffness Regression Over 12 Months Post-treatment","volume":"63","author":"Chan","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_25","first-page":"2347","article-title":"Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection","volume":"23","author":"Carrasco","year":"2018","journal-title":"AIDS"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2011055","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of Direct-Acting Antiviral Treatment with Mortality Among Medicare Beneficiaries with Hepatitis C","volume":"1","author":"Kalidindi","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/jvh.13482","article-title":"Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis","volume":"28","author":"Sahakyan","year":"2021","journal-title":"J. Viral. Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of Direct-Acting Antiviral Therapy with Liver and Nonliver Complications and Long-term Mortality in Patients with Chronic Hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2019.02.002","article-title":"Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study","volume":"399","author":"Marciniewicz","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tagliapietra, M., and Monaco, S. (2020). Neuroimaging Findings in Chronic Hepatitis C Virus Infection: Correlation with Neurocognitive and Neuropsychiatric Manifestations. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072478"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Taha, G., Ezra, L., and Abu-Freha, N. (2023). Hepatitis C Elimination: Opportunities and Challenges in 2023. Viruses, 15.","DOI":"10.3390\/v15071413"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1118227","DOI":"10.3389\/fpubh.2023.1118227","article-title":"A systematic review of barriers and facilitators for hepatitis B and C screening among migrants in the EU\/EEA region","volume":"15","author":"Moonen","year":"2023","journal-title":"Front. Public Health"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/9\/1872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:46:45Z","timestamp":1760129205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/9\/1872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["life13091872"],"URL":"https:\/\/doi.org\/10.3390\/life13091872","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}